It is reported that Dox induces isoform-specific deacetylation and nuclear accumulation of γ2, triggering nucleolar stress and p53-mediated apoptosis and suggested a promising cardio-oncology strategy that combines HDAC inhibitors with Dox to mitigate DIC.
Abstract
Doxorubicin (Dox)-induced cardiomyopathy (DIC), characterized by cardiomyocyte apoptosis, remains a major clinical challenge in chemotherapy. The regulatory γ2 subunit of AMP-activated protein kinase (AMPKγ2) plays a key role in cardiovascular diseases, but its function in DIC is poorly understood. Here, we report that Dox induces isoform-specific deacetylation and nuclear accumulation of γ2, triggering nucleolar stress and p53-mediated apoptosis. Mechanistically, HDAC3 and TIP60 interact with γ2 and modulate the acetylation of multiple lysine residues within its nuclear localization signal (NLS), controlling its nucleocytoplasmic shuttling. Dox enhances HDAC3-mediated γ2 deacetylation, thereby driving nuclear accumulation of the γ2-containing AMPK (γ2-AMPK) while suppressing the cytosolic AMPK activity. Nuclear γ2-AMPK phosphorylates and inactivates TIF-IA, a key RNA polymerase I-specific transcription initiation factor, leading to nucleolar stress through inhibition of rRNA transcription. rRNA deficit triggers release of free ribosomal proteins (RPs), which bind to and inhibit the E3 ubiquitin ligase MDM2, resulting in p53 stabilization and activation of apoptotic signaling. Using genetically engineered cardiomyocytes and a DIC mouse model, we found that a deacetyl-mimetic γ2 mutant (6KR) exacerbated DIC, whereas an acetyl-mimetic mutant (6KQ) was cardioprotective. Collectively, our findings establish acetylation-driven nuclear translocation of γ2 as a critical node linking Dox-induced nucleolar stress to p53-dependent apoptosis and suggest a promising cardio-oncology strategy that combines HDAC inhibitors with Dox to mitigate DIC. Significance statement Doxorubicin is an effective cancer drug, but its use is limited by cardiomyopathy. Our study reveals that doxorubicin drives HDAC3-mediated deacetylation of AMPKγ2, exposing its nuclear localization signal and redirecting γ2-containing AMPK from the cytoplasm to the nucleus. Nuclear AMPKγ2 phosphorylates TIF-IA, suppresses ribosomal RNA synthesis, and activates a nucleolar stress pathway that stabilizes p53 and promotes cardiomyocyte apoptosis. In mice, a deacetylation-mimetic AMPKγ2 mutant worsens doxorubicin-induced cardiomyopathy, whereas an acetylation-mimetic mutant is protective. These findings uncover an acetylation-controlled spatial switch in AMPK signaling and identify the AMPKγ2 deacetylation–nucleolar stress axis as a potential target for reducing chemotherapy-associated cardiac injury.
Synaptotagmin-binding cytoplasmic RNA-interacting protein (SYNCRIP) is an RNA-binding protein (RBP) implicated in the pathogenesis of various cancers through involvement in regulating multiple cellular processes. Notably, this study identified that SYNCRIP expression is significantly elevated in glioblastoma (GBM) and is associated with poor prognosis and tumor progression. Mechanistically, SYNCRIP upregulates SIRT1 expression at both the transcriptional and post-transcriptional levels by stabilizing SIRT1 mRNA. Meanwhile, loss of SYNCRIP leads to reduced SIRT1 expression, accumulation of reactive oxygen species (ROS), and induction of ferroptosis. Notably, restoration of SIRT1 rescues cells from ferroptotic cell death, supporting the critical role of SIRT1 in SYNCRIP-mediated ferroptosis resistance. SYNCRIP also enhances hexokinase 2 (HK2) expression through transcriptional activation and internal ribosome entry site (IRES)-mediated translation, thereby promoting glycolytic activity in GBM. Furthermore, depletion of SYNCRIP results in mitochondrial dysfunction and impairs GBM cell migration and invasion by downregulating epithelial-mesenchymal transition (EMT)-associated factors. Collectively, these findings suggest that SYNCRIP is a key regulator of GBM progression by maintaining metabolic homeostasis and ferroptosis resistance, highlighting SYNCRIP as a potential therapeutic target in GBM.
Hyeon Ji Kim, Hyo-Jin Song, Yu Gyung Kim et al.· International Journal on Bio...· 0 citations
SIRT1–GAPDH signaling represents a post-translational axis linking sirtuin activity directly to glycolytic enzyme function, distinct from SIRT1's traditional transcriptional roles and serving as a viable molecular checkpoint in microglial immunometabolism.
Chou-Yi Hsu, I. Sapaev, O. Nematov et al.· Frontiers in Immunology· 0 citations
As the roles of poly-ADP-ribose polymerase 7 (PARP7) in tumor immune evasion become increasingly well defined, PARP7 inhibitors have emerged as a promising class of anticancer therapeutics. To date, phase I clinical trials of PARP7 inhibitors have reported no significant cardiovascular adverse events. However, PARP7's involvement in doxorubicin (DOX)-induced cardiotoxicity (DIC), a major clinical limitation of widely used chemotherapeutics, remains poorly understood. Elucidating the functional role of PARP7 in this pathological context is essential for evaluating the therapeutic safety of pharmacological PARP7 inhibition. This study aimed to define the functional role and molecular mechanism of PARP7 in DIC. We demonstrate that PARP7 is robustly and selectively upregulated in cardiomyocytes following DOX exposure. Genetic ablation of PARP7 markedly attenuates DIC. Mechanistically, we identify glutathione peroxidase 4 (GPX4) as a direct ADP-ribosylation substrate of PARP7. PARP7 catalyzes mono-ADP-ribosylation of GPX4, leading to its loss of enzymatic activity. In addition, this suppression of GPX4 is both necessary and sufficient for PARP7-driven ferroptosis in cardiomyocytes. Importantly, cardiomyocyte-specific PARP7 knockdown, achieved via AAV9-cTNT-mediated delivery of short hairpin RNA, effectively reverses established DIC, confirming its therapeutic relevance in clinical translation. Collectively, these findings establish PARP7 as a druggable, cardiomyocyte- specific regulator of ferroptosis and define the PARP7-GPX4 axis as a mechanistically grounded, therapeutically targetable pathway in cardio-oncology.
Y. Lyu, Lintao Wang, Xiao-Wen Shi et al.· Translational Research: The...· 0 citations